OOIR: Observatory of International Research

Papers

(The TQCC of Pharmacoeconomics is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Authors’ Reply to Comment on “Risk-Adjusted Performance Measures”	172
Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling	149
Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children	85
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy	79
Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment	69
Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?	63
The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis	59
The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment	49
The Egyptian EQ-5D-5L Extensive Pilot Study: Lessons Learned	49
Bayesian Meta-Analysis: A Practical Introduction	46
Advancing Methods to Measure and Reward Healthcare Innovation	46
Innovation Headroom for a Highly Accurate PD-L1 Companion Diagnostic in Non-small Cell Lung Cancer	46
Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based	45
Cost Effectiveness of Strategies to Manage Atrial Fibrillation in Middle- and High-Income Countries: A Systematic Review	42
Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK and the USA	42
Under-reporting of Validation Efforts for Health Economic Models Persists Despite the Availability of Validation Tools: A Systematic Review	40
Economic Burden Associated with Pulmonary Arterial Hypertension in the United States	40
Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies	39
The Economic Burden of Inflammatory Arthritis: A Systematic Review	38
Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling	37
Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy	35
Caring for and Caring about in Economic Evaluation: Modelling the Family and Caregiving Effects	34
De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation	34
EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions	33
Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review	32

Time to Close the Gap Between Guidelines and the Reimbursement Policy for Diabetes Treatment in Turkey	31
A Framework for Reliable, Transparent, and Reproducible Population-Adjusted Indirect Comparisons	31
Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition	30
The Use of Real-World Data for Estimating Relative Treatment Effects in NICE Health Technology Assessment Submissions: A Review	29
Mixture and Non-mixture Cure Models for Health Technology Assessment: What You Need to Know	28
A Framework for Integrating Continuous Glucose Monitor-Derived Metrics into Economic Evaluations in Type 1 Diabetes	28
An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada	28
Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective	28
The Difference Method Approach for Sampling Order Constrained Parameters: An Improved Implementation and Important Limitations	26
The Value of Combination Vaccines in Children and Adults: More than the Sum of Their Parts	25
Economic Evaluations of Treatments for Duchenne Muscular Dystrophy: The Caregiver QALY Trap	25
Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease: An Updated Methodological Review	25
A Systematic Review of Methods for Estimating Productivity Losses due to Illness or Caregiving in Low- and Middle-Income Countries	24
Market Transparency in Medicine Pricing: Pathways to Fair Pricing	24
Caregiver Burden of Spinal Muscular Atrophy: A Systematic Review	24
The Cost Effectiveness of Upgrading Cochlear Implant Sound Processors in Australia: A Novel Application of Individual-Level Microsimulation Models	24
Identifying and Comparing Intervention Cost Components in Remote Patient Monitoring: A Scoping Review	23
Prognostic Testing for Prostate Cancer—A Cost-Effectiveness Analysis Comparing a Prostatype P-Score Biomarker Approach to Standard Clinical Practice	22
Improving Transparency of Decision Models Through the Application of Decision Analytic Models with Omitted Objects Displayed (DAMWOOD)	22
Drug Pricing Stewardship from Mark Cuban’s Cost Plus Generic Drug Program	22
Psychometric Performance Comparison of the Adapted versus Original Versions of the EQ-5D-Y-3L and -Y-5L in Proxy Respondents for 2- to 4-Year-Olds	21
Measuring the Direct Medical Costs of Hospital-Onset Infections Using an Analogy Costing Framework	21
Value-Based Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs	20
Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia	20
Value of Information for Clinical Trial Design: The Importance of Considering All Relevant Comparators	20
Quality Appraisal in Systematic Literature Reviews of Studies Eliciting Health State Utility Values: Conceptual Considerations	20
Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry	19
Comparison of EQ-5D-Y-3L Utility Scores Using Nine Country-Specific Value Sets in Chinese Adolescents	19
A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)	19
Acknowledgement to Referees	19
Economic and Humanistic Burden of Osteoarthritis: An Updated Systematic Review of Large Sample Studies	19
Accounting for Genomic Testing Costs in Cost-Effectiveness Evaluations: Challenges and Lessons Learned from the NICE Single Technology Appraisal of Erdafitinib for Treating Unresectable or Metastatic	18
Application of Multi-level Network Meta-Regression in the NICE Technology Appraisal of Quizartinib for Induction, Consolidation and Maintenance Treatment of Newly Diagnosed FLT3-ITD-Positive Acute Mye	18
Development and Validation of txSim: A Model of Advanced Lung Cancer Treatment in Australia	18
Balancing Innovation and Access: Insights from AIM’s Fair Pricing Model and Its Current and Future Applications	18
Re-anchoring the Value of Innovative Therapies in NICE Decision Making When Comparators are Cost Ineffective: A Case Study of Late-Onset Pompe Disease	18
A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models	18
Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria	17
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China	16
Comparing Generic Paediatric Health-Related Quality-of-Life Instruments: A Dimensionality Assessment Using Factor Analysis	16
Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer	16
Modelling the Cost-Effectiveness of Diagnostic Tests	16
Systematic Literature Review to Identify Cost and Resource Use Data in Patients with Early-Stage Non-small Cell Lung Cancer (NSCLC)	16
Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants: An Analysis Including All-Infant Protection	15
A Proposal of a Cost-Effectiveness Modeling Approach for Heart Failure Treatment Assessment: Considering the Short- and Long-Term Impact of Hospitalization on Event Rates	15
Comment on “An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia”	15
Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis	15
Capturing Value Attributes in the Economic Evaluation of Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections in the United Kingdom	15
Cost-Effectiveness of Thrombopoietin Mimetics in Patients with Thrombocytopenia: A Systematic Review	15
Uncertainty in Matching-Adjusted Indirect Comparisons Using Real-World Evidence: Evidence Assessment Group Perspective	15

Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA	14
Systematic Review of the Relative Social Value of Child and Adult Health	14
Health Care Resource Utilization and Costs Associated with US Medicaid Sobriety Restrictions on Direct-Acting Antivirals for Hepatitis C Virus: A Retrospective Claims Database Analysis	14
How do Health State Values Differ When Respondents Consider Adults Versus Children Living in Those States? A Systematic Review	14
Measuring the Indirect Cost of Illness Using EQ-5D-5L While Accounting for Job Characteristics	14
A Guide to an Iterative Approach to Model-Based Decision Making in Health and Medicine: An Iterative Decision-Making Framework	14
Childhood Transitions Between Weight Status Categories: Evidence from the UK Millennium Cohort Study	14
The Costs of Dementia in Europe: An Updated Review and Meta-analysis	13
Comment on “The Importance of Structured Expert Elicitation to Inform Outcomes Following Treatment Discontinuation: Evidence Assessment Group Perspective”	13
Economic Implications of Endometriosis: A Review	13
The Cost-Effective Price of Lecanemab for Patients with Early Alzheimer’s Disease in Sweden	13
Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments	13
Carers’ Health-Related Quality of Life in Global Health Technology Assessment: Guidance, Case Studies and Recommendations	13
Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments	12
Cost-Effectiveness Analysis of MammaPrint® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer	12
Considerations Around the Inclusion of Children and Young People’s Time in Economic Evaluation: Findings from an International Delphi Study	12
Content Comparison of Quality-of-Life Instruments Used in Economic Evaluations of Sleep Disorder Interventions: A Systematic Review	12
Economic Evaluation of Interventions to Reduce Antimicrobial Resistance: A Systematic Literature Review of Methods	12
Examining the Effect of Depicting a Patient Affected by a Negative Reimbursement Decision in Healthcare on Public Disagreement with the Decision	12
Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of Bias	12
Informal Caregiving Provision for Disabled or Elderly in the Families and Work Productivity: Evidence from 11 Waves of an Australian Population-Based Cohort	12
A Value Set for the EQ-5D-Y-3L in the Netherlands	12
Current Practices for Accounting for Preference Heterogeneity in Health-Related Discrete Choice Experiments: A Systematic Review	12
A Systematic Review of the Economic Burden of Prostate Cancer: Direct and Indirect Cost Perspectives	12
Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective?	12
Societal Versus Healthcare Perspectives on the Cost Effectiveness of Ocrelizumab for Treatment of Primary Progressive Multiple Sclerosis in Aotearoa New Zealand	12
A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process	11
Universal Health Coverage of Opioid Agonist Treatment in Norway: An Equity-Adjusted Economic Evaluation	11
Correction: Health-Related Quality-of-Life Outcomes of Very Preterm or Very Low Birth Weight Adults: Evidence From an Individual Participant Data Meta-Analysis	11
Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan	11
Economic Evaluation of Pre-emptive Pharmacogenetic Panel Testing versus No Genetic Testing in a Multi-ethnic Asian Population	11
MPES-R: Multi-Parameter Evidence Synthesis in R for Survival Extrapolation—A Tutorial	11
Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meni	10
Analytical Considerations When Anchoring Discrete Choice Experiment Values Using Composite Time Trade-Off Data: The Case of EQ-5D-Y-3L	10
Incorporating Complexity and System Dynamics into Economic Modelling for Mental Health Policy and Planning	10
Correction: How do Health State Values Differ When Respondents Consider Adults Versus Children Living in Those States? A Systematic Review	10
Informal Care Costs According to Age and Proximity to Death to Support Cost-Effectiveness Analyses	10
Conceptual Framework for Optimised Proxy Value Set Selection Through Supra-National Value Set Development for the EQ-5D Instruments	10
Beyond the States: Developing a Discrete Event Simulation Model Using R	10
Measuring Effectiveness Based on Patient Experience (Instead of QALYs) in US Value Assessments	10
HTA Barriers for Conditional Approval Drugs	9
Are Health Gains to Children and Adolescents More Important Than Health Gains to Adults? A Person Trade-Off Study	9
Schrodinger’s Pricing: Conceptual and Practical Challenges of Conditional PAS in the NICE Technology Appraisal of Lorlatinib for Untreated ALK-Positive Advanced Non-small-cell Lung Cancer (Review of T	9
Using AI in the Economic Evaluation of AI-Based Health Technologies	9
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK	9
Does the Informal Carer Identification Method Matter? Evidence from Self-Declaration and Time Diary Approaches	9
Discrete-Event Simulation Modeling Framework for Cancer Interventions and Population Health in R (DESCIPHR): An Open-Source Pipeline	9
PharmacoEconomics Supplement	9
Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study	9
Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzer	9
Developing a Framework of Cost Elements of Socioeconomic Burden of Rare Disease: A Scoping Review	9